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Abstract 
Deficits in the ability to recognize and think about mental states are broadly understood to be a 
root cause of promote dysfunction in Borderline Personality Disorder (PD). This study compared 
the magnitude of those deficits relative to other serious mental illness or psychiatric conditions. 
Assessments were performed using the metacognition assessment scale-abbreviated (MAS-A), _________________________________________________________________________________
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emotional recognition using the Bell Lysaker Emotional Recognition Test and alexithymia using 
the Toronto Alexithymia Scale among adults with schizophrenia (n=65), Borderline PD (n=34) 
and Substance Use disorder without psychosis or significant Borderline traits (n=32).  ANCOVA 
controlling for age revealed the Borderline PD group had significantly greater levels of 
metacognitive capacity on the MAS-A than the schizophrenia group and significantly lower 
levels than the Substance Use group. Multiple comparisons revealed the Borderline PD group 
had significantly higher self-reflectivity and awareness of the other’s mind than the 
schizophrenia group but lesser mastery and decentration on the MAS-A than substance use 
group, after controlling for self-report of psychopathology and overall number of PD traits.  The 
Borderline PD and Schizophrenia group had significantly higher levels of alexithymia than the 
substance use group. No differences were found for emotion recognition. Results suggest 
metacognitive functioning is differentially affected in severe mental disorders.  
 
 
1. Introduction 
Alterations in the ability to recognize and think about one’s own and others’ mental states 
is a hallmark of Borderline Personality Disorder (Borderline PD). Deficits in these abilities, 
referred to using the related constructs of metacognition (Semerari et al., 2003), social cognition 
(Roepke et al., 2013) and mentalizing (Bateman and Fonagy, 2004; Fonagy, 1991) have been 
proposed as underlying causes of many characteristic Borderline PD behaviors including stormy 
interpersonal relationships, lack of a core sense of identity, affective instability, and chronic 
failure to effectively respond to psychological and social challenges (Fonagy et al., 2002; 
Roepke et al., 2013; Semerari et al., 2007). 
  
Research on metacognition, social cognition and mentalization in Borderline PD includes 
at least two types of studies. First, research has examined the association of Borderline PD with 
deficits recognizing different kinds of internal states. This has revealed mixed results. 
Heightened levels of alexithymia have been found in Borderline PD (Joyce et al., 2013; Lecours 
and Bouchard, 2011; McMain et al., 2013; Peter et al., 2013) though there have been some 
failures to replicate this (Nicolò et al., 2011). Difficulties correctly recognizing others’ emotions 
has been found in some but not all studies (Dziobek et al., 2011; Hepp et al., 2016; Lowyck et 
al., 2016; Niedtfeld et al. 2017).  Borderline PD has been more consistently linked with 
difficulties detecting others’ motives especially in complex and emotionally charged situations 
(Brüne et al., 2016; Ghiassi et al., 2010; Peter et al., 2013; Petersen et al., 2016; Preißler et al., 
2010; Sharp et al., 2011). It has also been suggested that patients with Borderline PD tend to 
over-ascribe mental states to others (Searles, 1996), or hypermentalize (Sharp et al., 2013). 
A second group of studies has focused whether there are prominent difficulties forming 
and using more complex integrated representations about the self and others in Borderline PD 
(Dimaggio et al., 2007; Ha et al., 2013). Semerari et al. (2005; 2014; 2015) found Borderline PD 
was less linked to the ability to describe cognitions and emotions, and more closely associated 
with difficulties forming complex ideas about their own changing mental states within the flow 
of life. Dimaggio et al. (2009) additionally found Borderline PD patients had unique difficulties 
seeing how the world could be perceived from the perspective of the other, or adopting a 
decentered stance. Outcalt et al. (2016) found that deficits in metacognitive mastery, or the 
ability to use metacognitive knowledge to respond to psychosocial challenges, moderated the 
relationship of anxious attachment to the severity of symptoms of Borderline PD. It has also been 
suggested that persons with Borderline PD are generally able to understand both the thoughts and 
  
feelings of the others, but struggle when situations demand more complex reflections about what 
is happening within the flow of that situation (Carcione et al., 2011).  
Since the earliest work which sought to define the disorder, Borderline PD has been 
conceptualized as involving disturbances in sense of self and others that are qualitatively 
different than those found in schizophrenia (Hoch and Polatin, 1949; Stone, 1977). Yet it 
remains unclear whether the deficits noted in Borderline PD are in fact unique relative to those 
experienced in schizophrenia, a condition with known metacognitive and social cognitive deficits 
(Lysaker et al., 2015). There are several reasons to suppose that persons with Borderline PD 
should have a different pattern of impairment than persons with schizophrenia. First, the 
presence of different kinds of metacognitive impairments are suggested by the differing form of 
psychosocial impairment in the two disorders. While in schizophrenia there are more likely to be 
tenuous social connections, in Borderline PD there are more likely to be stormy and unstable 
ones. Second, the hypothesized roots of social cognitive and metacognitive dysfunctions are 
different between the groups. In schizophrenia, anomalous self-experience and neurocognition 
have been proposed to contribute to these deficits (Lysaker et al., 2013), while disturbances in 
attachment and the abilities to manage emotion have been proposed as causal factors in 
Borderline PD (Fonagy et al., 2002). Consistent with this are studies that participants with 
schizophrenia performed more poorly on Theory of Mind tasks tending to show a lack of 
mentalization while the errors of participants with Borderline PD were the result of 
hypermentalizing (Andreou et al.; 2015; Vaskinn et al., 2015). Examining difficulties 
synthesizing self-experience, Pec et al. (2014) reported that patients with Borderline PD showed 
slightly different levels of splitting compared to patients with schizophrenia which were linked 
  
with history of trauma and additionally had unique correlations with dose of antipsychotic 
medication.  
Nevertheless, patients diagnosed with both conditions do experience social alienation, 
stigma and demoralization (Rüsch et al., 2006), factors that are known to affect the ability to 
recognize and reason about mental states which they disrupt basic trust and motivation for 
interpersonal connection. Patients with Borderline PD are also prone to experiencing transient 
psychotic symptoms. Thus, it essential to investigate whether patients with Borderline PD and 
schizophrenia do indeed differ in their abilities to think about mental states and if so how.  
To explore this issue, the current study compared the abilities of persons with 
schizophrenia, Borderline PD and substance use disorder to accurately recognize two specific 
elements of mental states: one’s own emotions (alexithymia) and the emotions of others, and to 
synthesize that information into complex and integrated ideas about the self and others. We 
selected alexithymia and emotion recognition as both are closely tied to the ability to respond to 
emergent social experience and have been identified as areas of need in the literature noted 
above. We chose metacognition as it allows for the separate measurement of self-reflectivity, 
awareness of other’s mental states, decentration and metacognitive mastery, casting each as a 
spectrum of activities which vary according to the extent by which they are synthesized into 
complex integrated representations (Lysaker et al., 2013; Semerari et al., 2003). We chose 
substance use disorder as a third psychiatric condition as it a common comorbidity of Borderline 
PD linked with deficits in the ability to reflect about mental states (Dimaggio et al., 2015; 
Morken et al., 2014), including alexithymia (Bashapoor et al., 2015; Taylor et al., 1997) and 
deficits recognizing the intentions (Maurage et al., 2015) and emotions of others (Nandrino et al., 
2014). Of note, work on substance use and social cognition has generally failed to consider the 
  
potential effects of comorbid PD traits, leaving it unclear to what extent these findings reflect 
substance use or comorbid Borderline PD traits.  
 Our primary aim was to test whether persons with Borderline PD performed differently 
on assessments of alexithymia, emotion recognition and metacognition, relative to persons with 
schizophrenia and persons with substance use disorder. We made several predictions. First, 
based upon earlier work (Carcione et al., 2011; Dimaggio et al., 2009; Semerari et al., 2005; 
2014; 2015; Outcalt et al., 2016; Semerari, 1999) we predicted that the Borderline PD group’s 
levels of alexithymia and deficits in affect recognition  would be less than what is observed in 
the schizophrenia group but greater than the deficits associated with the substance use group. 
While previous work has linked substance use disorders to alexithymia and deficits in emotion 
recognition, that work generally did not account for the presence of Borderline PD traits and 
hence we reasoned that a substance abuse group that did not include persons with Borderline PD 
would have less severe overall levels of impairment. Second, we predicted that overall 
metacognitive capacity of the Borderline PD group would be lesser than the substance use group 
and higher than the schizophrenia group. Third, we predicted that the Borderline PD group 
would have lower levels of two specific forms of metacognition: 1) Decentration, and 2) 
Mastery, the ability to use metacognitive knowledge to respond to stress. We anticipated this 
metacognitive profile given literature that while many with Borderline PD can make basic 
guesses about others’ emotions, and express their own distress, they may fail to see the 
perspective of others or use knowledge of themselves when distressed (Caricone et al., 2011; 
Dimaggio et al., 2009; Outcalt et al. 2016; Sharp et al., 2013). 
 We also had a secondary and exploratory aim of comparing the strength of the 
relationships between metacognitive domains across groups. We hypothesized that the 
  
metacognitive capacities of the schizophrenia group would be more closely related given 
literature suggesting that metacognitive deficits in schizophrenia are more global and trait like in 
nature, while in Borderline PD, impairments are hypothesized to be context dependent and 
responsive to interpersonal factors in the moment (Fonagy et al., 2002; Liotti et al., 2008; Brüne 
et al., 2016; Ghiassi et al., 2010). Regarding the relationship of different elements of 
metacognition to one another in the substance use group, we made no predictions but considered 
those results to offer potential preliminary insights into how different metacognitive dimensions 
may influence one another or covary.  
 
2. Method 
2. 1 Participants  
Thirty-four adults who met criteria for Borderline PD, as assessed with Structured 
Clinical Interview for DSM-IV Axis II Personality Disorders (First et al.,  1997), 32 adults with a 
diagnosis of a Substance Use Disorder and without a diagnosis of a psychotic disorder as per the 
Structured Interview for DSM-IV Disorders-II (SCID; Spitzer et al., 1994) and 65 adults with the 
SCID-I confirmed diagnoses of Schizophrenia Spectrum Disorder  (Schizophrenia, n = 43;  
schizoaffective disorder, n = 22) were recruited from a VA Medical Center. All participants were 
receiving ongoing outpatient treatment and were in a post-acute or stable phase of their disorder, 
defined as no hospitalizations or changes in medication or housing in the last month. Participants 
were referred by their clinicians. Demographics per group are reported in Table 1. 
Participants reported in this study participated in one of three studies. The schizophrenia 
group was recruited for a study of the effects of cognitive therapy on work outcome. Exclusion 
criteria in this study included active substance dependence. The Substance Use group was 
  
recruited for a study of metacognitive correlates of treatment outcome. Exclusion criteria for this 
study included schizophrenia or bipolar disorder as assessed with the SCID and three or more 
Borderline PD traits as assessed with the SCID-II. We allowed the substance use group to have 
two or fewer Borderline PD traits reasoning that these traits are common in substance use and 
hence to require the presence of no traits might reduce the representativeness of the group. Also, 
by limiting permissible Borderline PD traits to two or fewer, will prevent the substance use 
group from being too similar to the Borderline PD group. The Borderline PD participants came 
from two separate studies which were investigating the metacognitive correlates of personality 
and attachment (n = 23) and the metacognitive correlates of treatment outcome (n = 11). In these 
two studies, the only significant methodological difference was that in the latter study comorbid 
substance use was assessed, and schizophrenia and bipolar disorder were ruled out with the 
SCID-I, while in the former study substance use was assessed, and schizophrenia and bipolar 
disorder were ruled out with the Mini International Neuropsychiatric Interview (MINI) (Sheehan 
et al., 1998). The baseline assessment of the Schizophrenia group did not include the SCID-II nor 
assessment of current substance use disorders, beyond ruling out current substance dependence.  
 
2.2 Instruments  
Indiana Psychiatric Illness Interview (IPII; Lysaker et al., 2002) is a semi-structured 
interview typically lasting 30 to 60 minutes. Responses are audio taped and later transcribed. The 
interviewer asks participants to discuss: i) the story of their life in general, ii) whether they think 
they have a mental illness and, if so, the ways that it has affected and not affected their life, iii) 
how this condition controls and is controlled by them; iv) how it affects, and is affected by 
others, and v) what they see in the future. The IPII differs from other psychiatric interviews in 
  
that minimal prompts are introduced and metacognitive capacities appear spontaneously. The 
IPII does not produce quantitative scores on its own but is one of several sources from which the 
Metacognition Assessment Scale-Abbreviated can be used to rate metacognition. 
2.2.1 Metacognition Assessment Scale- Abbreviated (MAS-A; Lysaker et al., 2005) 
The MAS-A is a rating scale, adapted from the MAS (Semerari et al., 2003), that assesses 
synthetic metacognitive capacities or the ability to synthesize discrete pieces of information into 
an integrated representation. This assessment is rated on the basis of the IPII and produces four 
scores and a total score which is the sum of those four scores. The first subscale, Self-
reflectivity, is a 9-point scale that gauges one’s ability to form ideas about oneself in an 
increasingly plausible and integrated manner. The second subscale, Awareness of the Mind of 
the Other, is a 7-point scale that assesses one’s ability to form ideas about others in an 
increasingly plausible and complex manner. The third subscale, Decentration, is a 3-point scale 
that addresses one’s ability to form ideas about oneself and others within the context of the larger 
world. The last subscale, Mastery, is a 9-point scale that assesses one’s capacity to use 
knowledge of oneself and others to respond to psychological and social challenges. For all four 
scales, higher scores indicate greater capacity for metacognition.  
The MAS-A has been found to have good inter-rater reliability with intra-class 
coefficients ranging from 0.71 to 0.91 (Lysaker at al., 2005). Regarding validity, MAS-A scores 
have been associated with assessments of awareness of illness, complexity of social schemas, 
preferences for active coping, and cognitive insight (c.f. Lysaker et al., 2015).  
2.2.2 Toronto Alexithymia Scale – 20 (TAS-20; Bagby et al., 1994a)  
The TAS-20 is a 20-item self-report measure of alexithymia. Items are rated using a five-
point Likert scale, with participants indicating level of agreement with statements that assess 
  
both the affective and cognitive elements related to recognizing one’s own emotions. Total 
scores range from 20 to 100, with higher scores indicating greater degree of alexithymia. Though 
the present study analyzed alexithymia as a dimensional construct, it has been suggested that 
scores exceeding 60 are indicative of clinically significant alexithymia (Taylor and Taylor, 
1997). In addition to a total score, the TAS-20 yields three factor scores: difficulty identifying 
feelings, difficulty describing feelings, and externally-oriented thinking. Evidence of acceptable 
internal consistency, test-retest reliability, and construct, concurrent, and convergent validity has 
been reported (Bagby et al., 1994a; 1994b).  
2.2.3 Bell-Lysaker Emotional Recognition Task (BLERT; Bell et al., 1997)  
The BLERT is a measure of ability to identify affect cues in videotaped stimuli. 
Participants are presented with 21-videotaped segments and asked to correctly identify the 
affects portrayed. Data on the adequacy of the BLERTs reliability and validity have been 
reported elsewhere (Bell et al., 1997; Bryson et al., 1997). 
2.2.4 Symptom Checklist-90-R (SCL-90-R; Derogatis, 1977)  
The SLC-90-R is a 90 item self-report inventory which was primarily designed to reflect 
the psychological symptom patterns of psychiatric and medical patients. It is a measure of 
current (state) psychological symptom status. The SCL-90-R measures nine primary symptom 
dimensions and generates an estimate of global psychopathology. For the purposes of this study 
we were interested in the score reflective of general psychopathology, the global severity index 
(GSI). Information regarding reliability including acceptable coefficient alpha have been 
reported elsewhere (Outcalt et al., 2016). 
2.2.5. Mini International Neuropsychiatric Interview (MINI; Sheehan et al., 1998)  
  
The MINI is a brief structured clinical interview which produces diagnoses of several 
psychiatric disorders as defined by DSM-IV and ICD-10. For the purposes of this study we 
sought to rule out the presence of schizophrenia, and bipolar disorder. 
2.3 Procedure 
 Institutional research review committees approved all procedures. Following informed 
written consent, diagnoses were determined using the SCID-I and II or MINI.  Participants were 
administered the IPII, TAS, and BLERT. Participants in these analyses came from three different 
studies as noted above. Participants in the Borderline PD group and the Substance Use group 
also completed the SCL-90. Metacognition was rated from a transcription of the IPII using the 
MAS-A. MAS-A ratings were assessed blind to performance on the BLERT, TAS, SCL-90, and 
SCID-II. 
2.4 Analyses 
Analyses were performed in five steps. First, we planned to compare the Borderline PD, 
Substance Use and Schizophrenia Spectrum groups on demographic variables and comorbidities 
to determine the need for covariates in group comparisons. Second, an analysis of covariance 
(ANCOVA) was planned to be used to compare the MAS-A, TAS, and BLERT scores, 
controlling for any necessary covariates.  Fisher's Least Squared Differences test were planned to 
compare individual groups in instances in which there were significant overall group differences 
noted in the ANCOVA. Third, we planned to compare the SCL-90 GSI scores and overall 
number of other PD traits on the SCID-II (the total number of traits excluding the borderline 
traits) of the Borderline PD and Substance Use groups with an ANOVA. Fourth, if there were 
significant differences on these variables, we planned to repeat the comparisons  with another 
ANCOVA the MAS-A, TAS, and BLERT scores between the Borderline trait group and the 
  
Substance Use group adding the overall number of other PD traits on the SCID-II (the total 
number of traits excluding the Borderline traits) and the SCL-90 to rule out the possibility that 
group differences were merely the result of their having more overall PD traits or their having 
higher levels of global psychopathology. Finally, we planned to separately correlate the MAS-A 
subscales with one another. We planned then to compare the average intercorrelations of the 
MAS-A items between groups using the Fisher r to z transformation.  
3. Results 
As revealed in Table 1, the Substance Use group was significant younger than the 
Schizophrenia group. Groups did not differ on education, gender, or race.  Concerning 
comorbities, the group with Borderline PD had a median of 6 Borderline and 17 other (non-
Borderline) traits on the SCID-P, while the Substance use group had a median of 1 Borderline 
trait and 8 other (non-Borderline) traits on the SCID-II. Of the 34 participants in the Borderline 
PD group, 25 had comorbid diagnoses of lifetime substance use disorders. When the types of 
substance use disorders found in the Substance Use and Borderline PD groups with comorbid 
substance use were compared, equivalent proportions of participants were found to have specific 
diagnoses of alcohol use (26/32, 79% and 20/25 80%) for the Substance Use group and 
Borderline PD groups respectively), Cannabis (12/32, 38% and 7/25 28%) for the Substance Use 
group and Borderline PD groups, respectively, and Opiate Use disorder (8/32, 25% and 5/25 
20%) for the Substance Use group and Borderline PD groups respectively. There was a 
significantly greater proportion of cases of cocaine abuse in Substance Use than in the Borderline 
PD group (15/32, 47% and 4/25 16% respectively). 
ANCOVA controlling for age were then conducted comparing groups on MAS-A, TAS, 
and BLERT scores. As revealed in Table 2 the Schizophrenia group had significantly lower 
  
overall scores on the MAS-A than either of the two other groups. The Borderline PD group had 
significantly lower MAS-A scores than the Substance Use group. On the MAS-A subscales the 
Borderline PD and Schizophrenia group had significantly lower Decentration and Mastery scores 
than the Substance Use groups, while the Borderline PD and Substance Use groups had 
significantly higher Self-reflectivity and Awareness of the Other compared to the Schizophrenia 
group. The Borderline PD and Schizophrenia groups additionally had significantly greater scores 
on the TAS total and all its subscales. No differences were found for the BLERT total. 
As revealed in Table 1 the Borderline PD group had significantly more overall PD traits 
(excluding Borderline PD traits) and higher SCL-90 GSI scores. Previous comparisons in which 
these groups differed were then repeated as another ANCOVA controlling for overall PD traits 
(excluding Borderline PD traits) and the SCL-90 GSI. As revealed in Table 2 the groups 
continued to differ significantly on the MAS-A total, MAS-A Mastery subscale, the TAS total 
and TAS Identifying feelings subscale. 
In the final planned step, we correlated the MAS-A individual scales with one another, 
and separately for all three groups. The individual correlations are presented in Table 3. When 
summed to provide an overall estimate of how closely the scales were related to one another we 
found an average intercorrelation of 0.24 for the Borderline PD group, 0.29 for the Substance 
Use group and 0.63 for the Schizophrenia group. Using the Fisher r to z transformation we found 
that the average correlation of the Schizophrenia group was significantly greater than that 
Borderline PD (z = -2.26, p = 0.02) and the Substance Use (z = -1.97, p = 0.04) groups. The 
mean intercorrelation of the Substance Use and Borderline PD groups did not differ significantly 
(z = 0.21, p = ns).  
  
It was unexpected that the Borderline PD and Schizophrenia groups did not differ on the 
MAS-A Decentration subscale given frequent observations that patients with schizophrenia 
struggle to achieve any decentration at all. We therefore performed exploratory ad hoc analyses 
comparing the frequency of the lowest possible score (“0”) on Decentration for both groups.  
This revealed that significantly more participants in the schizophrenia group had scores of “0” 
(30 out of 65 or 46%) than participants in the Borderline PD Group (7 out of 34 or 21%; X
2
 = 
6.23; p = 01). By comparison, five of the 32 (16%) members of the Substance Use group also 
had a score of a “0” on Decentration. 
 Finally, there was high comorbidity of substance use disorders in the BPD group and to 
rule out the possibility that this accounted for any observed differences, we conducted T-Tests 
comparing the MAS-A, and TAS scores of those persons in the BPD group with and without a 
comorbid diagnosis. None of the comparisons were significant. 
4. Discussion 
The study had a primary aim of comparing the levels of metacognitive deficit, 
alexithymia and emotion recognition of patients with Borderline PD, schizophrenia and others 
with substance use disorder and a secondary aim to contrast the relationships of individual 
components of metacognition one another across the different clinical groups. As predicted, we 
found that the Borderline PD group had less severe impairments in metacognitive function than 
the Schizophrenia group, and more severe impairments than the group with Substance Use 
disorders. In contrast to the Schizophrenia group, the Borderline PD group was better able to 
reflect upon oneself and to make sense of the cognitive and affective functioning of others. In 
these domains, the ability of patients with Borderline PD were generally in the same range of 
persons with substance use disorder without significant levels of Borderline PD traits. In contrast 
  
to the Substance Use disorders group, the Borderline PD group was less able to understand that 
others view events from a perspective distinct from their own and unrelated to their needs. The 
Borderline PD group also had more difficulties in using knowledge of mental states for 
purposeful problem solving.  In these domains, Borderline PD patients demonstrated comparable 
metacognitive capacity to Schizophrenia group. Of note, the global differences in overall index 
for metacognition and mastery between the Borderline PD and the Substance Use group 
persisted after controlling for global psychopathology and presence of other PD traits and thus 
these findings were not merely a reflection of severity of PD or psychopathology. The difference 
in decentration by contrast was reduced to the level of a trend which suggested that general 
emotional distress may affect the capacity for decentration in the Borderline PD group.  
Although the cross-sectional nature of the data precludes drawing causal conclusions, 
results are generally consistent with emerging models of Borderline PD which suggest that this 
condition, relative to at least some other forms of mental disorder, may involve unique 
difficulties recognizing and thinking about mental states. These may include difficulties 
integrating information into reflections about the self and others and ultimately translating that 
information into meaningful action. This is consistent with work which has described how, at the 
level of content, the fragmentation of sense of self and others differs between persons with 
Borderline PD and schizophrenia and results in qualitatively different subjective experiences 
(Pec et al., 2014; Stone, 1977).   
Somewhat surprisingly, while the Borderline PD group reported higher levels of 
alexithymia than the Substance Use disorder group, their reported levels were equivalent to those 
of the schizophrenia group.  Furthermore, there were no overall differences found in affect 
recognition. This may suggest that there are some social cognitive deficits which are not specific 
  
to one kind of mental disorder. It may also suggest that other forms of social cognition such as 
unawareness of one’s own affect are equivalently affected in different forms of particularly 
severe mental illness. Importantly, the global differences in metacognition and alexithymia 
between the Borderline PD and the Substance Use groups persisted after controlling for global 
psychopathology and presence of other PD traits and thus this finding was not merely a 
reflection of severity of PD or psychopathology. This does suggest that the experience of 
alexithymia in Substance Use disorders may be considerably less than in Borderline PD and 
Schizophrenia. It also points to the possibility that previous work linking alexithymia with 
substance use may be partially a function of the presence of co-morbid Borderline PD. Of note, 
as with all unexpected findings, these interpretations should be taken as speculative and fodder 
for future research. 
Concerning the secondary exploratory aim of the study, which was to compare the 
relationships of individual components of metacognition with one another, as predicted, we 
found that the different domains of metacognition were more closely related in the Schizophrenia 
group relative to the Borderline PD group. This is consistent with the idea that the metacognitive 
problems in schizophrenia are of a global nature, while in Borderline PD some aspects of 
metacognition are more intact than others. Mean scores for this group indicated they are able to 
describe the self and the others’ cognitive and affective states and to reflect upon these, but not 
able to appreciate the perspectives of others (Semerari et al., 2005; 2014; 2015) nor use 
psychological knowledge for purposeful problem solving. Interestingly, the Substance Use 
disorder group also demonstrated a pattern relative to the Schizophrenia group, in which the 
scores of the metacognition scale were less significantly related to one another. 
  
  There are limitations of the study. Participants were mostly men in their 40s and 50’s 
involved in treatment. A different relationship may thus exist with the variables studied here 
among younger persons with schizophrenia, females, or among persons who decline treatment. 
Additionally, we used only one measurement of metacognition, alexithymia and emotion 
recognition, and all measurements occurred at only one point in time. Longitudinal research is 
necessary given the possibility of fluctuations levels of metacognitive function. Work is also 
needed to explore the potential effects of gender. Psychiatric history and stigma on these 
relationships. Additionally, the Substance Use and Borderline PD groups had a significant 
number of other kinds of PD traits, while the majority of the Borderline PD group had significant 
levels of other PD traits and more often than not also had a comorbid Substance Use disorder. 
Future work is needed with persons with Substance Use disorders who do not experience PD 
traits as well as Borderline PD in the absence of a Substance Use disorder. Work is also needed 
with healthy controls to examine how impaired subjects in each group were in terms of their 
metacognitive and social cognitive function relative to others without any form of mental illness. 
We also did not assess comorbid PD and substance use among the schizophrenia group, a 
common problem experienced by this group which could influence metacognition and 
alexithymia. Future work is needed with samples that contain more rarified groups without 
overlapping personality disorder traits and substance use issues. As all participants were in 
treatment, results may reflect the effects of treatment or the emotional state associated with help 
seeking. Finally, we used a specific measure which cued for reflections about life history and 
mental health concerns. It is possible that the metacognitive function of groups could be different 
in other interviews which called for greater or lesser degrees of affective involvement. Given 
observations regarding how qualitatively different the representations of self and others are in 
  
schizophrenia and Borderline PD (e.g. Freedman, 1980) future research is needed to qualitatively 
explore differences in representations of self and others.  
Taken together, this study, albeit only the start, offers evidence that adults with 
Borderline PD may experience unique deficits in metacognition. With replication, our findings 
may have several clinical implications. First, they support the idea that treatment of Borderline 
PD often needs to support the development of the capacity to reason about mental states 
(Bateman and Fonagy, 2004). It also is consistent with developing metacognitive interventions 
for PD more specifically focused on Mastery (Buck et al., in press; Dimaggio et al., 2007; 2015; 
Livesley, Dimaggio and Clarkin, 2016). It also suggests the need for therapies to move beyond 
helping persons to merely correctly recognize specific thoughts and feelings and instead to 
promote the capacity to create a complex and integrated sense of self in the world which may 
underpin the development of a sense of personal agency (Vohs et al., 2016; Buck et al., in press).  
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Table 1 Comparisons of demographics, personality disorder traits and overall symptom severity 
 1 2 3 F Post Hoc X
2
 
 Borderline Substance  Schizophren
ia 
ANOVA Compariso
ns 
 
 Personality  Use Spectrum  P < 0.05  
  
 Disorder Disorder      
 (n=34) (n=32) (n=65)    
 Frequency Frequency Frequency    
Gender (male/female) 27/5 31/1 62/3   4.48 
Race 
(Caucasian/African 
American) 
15/19 20/12 28/37   3.55 
 Mean (SD) Mean (SD) Mean (SD)    
Age 46.09(11.53
) 
43.00(10.0
1) 
50.38(11.00
) 
5.27* 2<3  
Education 12.69(1.57) 13.26(2.29) 12.83(2.21) 0.76   
Total Traits minus       
  Borderline 
Personality 
      
  Disorder Traits 19.72 (8.69) 8.47 (6.55)  28.73*** 1>2  
SCL 90 Global 
Severity 
55.27 
(10.84) 
42.12(8.96)  28.31*** 1>2  
  Index       
 
*P<0.05; ***P<0.001 
 
 
  
  
Table 2 Comparisons of metacognition, alexithymia, and affect recognition  
  1 2 3 F Post Hoc 
  Borderline Substance  Schizophrenia ANCOVA Comparisons 
  Personality  Use Spectrum F(2,128) = P< 0.05 
  Disorder Disorder     
  (n=34) (n=32) (n=65)   
  Mean (SD) Mean (SD) Mean (SD)   
MAS-A  Self-
reflectivity 
5.72(1.66) 6.28(1.63)  4.32(1.46) 15.39*** 2,1>3 
 Awareness 
of other 
3.75(0.94) 4.12(1.02)  2.78 (0.91) 23.70*** 2,1>3 
 Decentration  0.73(0.50) 1.42(1.32) 0.52(0.54) 10.86*** 2>1,3 
 Mastery  3.71(1.38) 4.50(1.18)  3.52(1.69) 3.65* 2>1,3
1
 
 Total 13.85(3.09) 16.40(3.53)  11.16(4.20)  18.99*** 2>1>3
1
 
TAS Describing 
Feelings 
16.44(3.97) 13.33 (5.53) 15.49 (3.82) 4.50* 2<1,3 
 Identifying 
Feeling 
22.94(5.89) 13.44 (6.72) 20.38 (6.30) 19.17*** 2<1,3
1
 
 Externally 
Oriented  
     
 Thinking  21.11 
(4.31) 
17.97 (4.66) 22.14 (3.61) 9.88**    2<1,3 
 Total 60.60 44.43 58.00 (11.85) 17.80***    2<1,3
1
 
  
(10.58) (12.68) 
BLERT 
Total 
 14.67 
(3.96) 
15.12(2.62) 13.34 (3.57) 1.54 ns 
 
*P<0.05; **P<0.001; ***P<0.001; 
1
post hoc comparisons between groups 1 and 2 remained 
significant at the 0.05 level after controlling for GSI T score and total number of personality 
disorder traits 
 
 
 
  
  
Table 3 Correlations among MAS-A scales between the three groups 
 Borderline PD Substance Use Schizophrenia Spectrum 
 (n=34) (n=32) (n =65) 
MA
S-A 
Scal
es 
S O D M S O D M  S O D M 
S - 0.41
* 
0.34 0.36* - 0.51** 0.41* 0.13 - 0.62*
* 
0.65
** 
0.57** 
O - - 0.44
* 
-0.11 - - 0.36* 0.13 - - 0.78
** 
0.60** 
D - - - 0.02 - - - 0.22 - - - 0.54** 
M - - - - - - - - - - - - 
 
S = Self Reflectivity; O = Awareness of the mind of the other; D = Decentration; M = Mastery; 
*P<0.05; ** P< 0.01 
  
  
 
 
Highlights 
 It is unknown how metacognitive deficits in Borderline Personality Disorder differ from 
those in schizophrenia  
 This study compared metacognition and social cognition among adults with 
schizophrenia, Borderline Personality Disorder and Substance Use disorders 
 Borderline Personality Disorder displayed a unique pattern of metacognitive deficits.  
 The Borderline Personality Group had greater deficits in decentration and mastery 
relative to reflectivity about the self and others.   
 
 
